Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Total Current Liabilities data on record, last reported at $17.9 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 90.74% to $17.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.9 million, a 90.74% increase, with the full-year FY2025 number at $19.0 million, up 117.28% from a year prior.
- Total Current Liabilities reached $17.9 million in Q1 2026 per RAPP's latest filing, down from $19.0 million in the prior quarter.
- Over the last five years, Total Current Liabilities for RAPP hit a ceiling of $19.0 million in Q4 2025 and a floor of $7.1 million in Q3 2024.
- A 4-year average of $11.7 million and a median of $9.4 million in 2025 define the central range for Total Current Liabilities.
- Peak YoY movement for Total Current Liabilities: dropped 0.41% in 2024, then skyrocketed 117.28% in 2025.
- Tracing RAPP's Total Current Liabilities over 4 years: stood at $8.8 million in 2023, then dropped by 0.41% to $8.8 million in 2024, then surged by 117.28% to $19.0 million in 2025, then decreased by 6.05% to $17.9 million in 2026.
- Business Quant data shows Total Current Liabilities for RAPP at $17.9 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.